

Keita Fujikawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8573263/publications.pdf>

Version: 2024-02-01

8
papers

22
citations

2258059

3
h-index

2272923

4
g-index

8
all docs

8
docs citations

8
times ranked

9
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of residual cognitive disturbances by early response of depressive symptoms to antidepressant treatments in patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2022, 296, 95-102.	4.1	5
2	Therapeutic Potential of Vortioxetine for Anhedonia-Like Symptoms in Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan. <i>Neuropsychiatric Disease and Treatment</i> , 2022, Volume 18, 363-373.	2.2	5
3	Early Improvement with Vortioxetine Predicts Response and Remission: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 3735-3741.	2.2	3
4	Health-Related Quality of Life Over 6 Months in Patients With Major Depressive Disorder Who Started Antidepressant Monotherapy. <i>Value in Health Regional Issues</i> , 2022, 30, 127-133.	1.2	3
5	Patient and Physician Perspectives of Depressive Symptoms and Expectations for Treatment Outcome: Results from a Web-Based Survey. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 2915-2924.	2.2	2
6	Diseases prevalent before major depressive disorder diagnosis: an exploratory nested case-control study using health insurance-based claims data. <i>BMJ Open</i> , 2022, 12, e048233.	1.9	2
7	Therapeutic Potential of Vortioxetine for Anxious Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan. <i>Neuropsychiatric Disease and Treatment</i> , 2021, Volume 17, 3781-3790.	2.2	2
8	Effect of omega-3 fatty acids on cardiovascular events in high-risk patients with hypertriglyceridemia in Japan: a 3-year post-marketing surveillance study (OCEAN3 survey). <i>Expert Opinion on Drug Safety</i> , 0, , 1-10.	2.4	0